a Background Nitric oxide (NO) is produced from L-arginine by NO synthase and is an important molecule with antiatherogenic properties. Asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of endothelial NO synthase. As such, it has been associated with endothelial dysfunction and elevated circulating levels of ADMA have been found in patients with cardiovascular risk factors. In addition, high baseline plasma levels of ADMA have been shown to be an independent predictor of adverse outcomes in a variety of patient populations. However, there are very limited data in patients with acute coronary syndromes (ACS).
Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography Background Nitric oxide (NO) is produced from L-arginine by NO synthase and is an important molecule with antiatherogenic properties. Asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of endothelial NO synthase. As such, it has been associated with endothelial dysfunction and elevated circulating levels of ADMA have been found in patients with cardiovascular risk factors. In addition, high baseline plasma levels of ADMA have been shown to be an independent predictor of adverse outcomes in a variety of patient populations. However, there are very limited data in patients with acute coronary syndromes (ACS).
Methods This study investigated the long-term prognostic significance of baseline plasma ADMA levels in a wellcharacterized cohort of 193 men with ACS who were referred for coronary angiography. All patients were followed up prospectively for the development of vascular outcomes.
Results After controlling for a variety of baseline variables (including established biomarkers such as high-sensitivity C-reactive protein and fibrinogen), plasma ADMA levels (analyzed as the upper tertile of baseline values compared with the lower two tertiles) were a strong and independent predictor of each of the individual endpoints of all-cause mortality [hazard ratio (HR): 2.45, 95% confidence interval
Introduction
Nitric oxide (NO) is produced from L-arginine by NO synthase and is an important antiatherogenic molecule, which is required for normal vascular function [1, 2] . Asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of endothelial NO synthase by competing with L-arginine as a substrate for NO synthase [3] . In this way, ADMA leads to endothelial dysfunction. There have been numerous clinical studies that have found elevated circulating levels of ADMA concentrations in patients with cardiovascular risk factors [4] [5] [6] [7] [8] . Furthermore, high levels of baseline ADMA have been shown to be independently predictive of adverse outcomes in a variety of patient populations, including those with diabetes [9, 10] , renal insufficiency [11] , peripheral vascular disease [12] , stable angina [13] , unstable angina [14] , as well as those with established coronary artery disease (CAD) [15] . However, there are only limited data in patients presenting with the full spectrum of acute coronary syndromes (ACS). Accordingly, the goal of this study was to investigate the utility of plasma levels of ADMA in a cohort of men referred for coronary angiography with an established diagnosis of an acute coronary syndrome, defined as unstable angina, non-STsegment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI).
Methods
This study was conducted at a Veterans Affairs Medical Center and was approved by the local institutional review board. The study population and design have been previously described in detail elsewhere [16, 17] . Briefly, 193 men (derived from an original database of 389 patients) undergoing diagnostic coronary angiography for the evaluation of ACS (12% with STEMI, 43% with NSTEMI, and 45% with unstable angina pectoris) constituted the study population. Fasting blood was obtained from all patients at the time of angiography for subsequent analysis. Using commercially available enzyme-linked immunosorbent assay kits, the levels of ADMA (DLD Diagnostika GmbH, Hamburg, Germany) and high-sensitivity C-reactive protein (hs-CRP; Life Diagnostics, West Chester, Pennsylvania, USA) were measured from aliquoted plasma samples. The sensitivities of hs-CRP and ADMA were 0.1 mg/l and 0.05 mmol/l, respectively. The intra-assay coefficients of variation for hs-CRP and ADMA were less than 7.6% and less than 7.5%, respectively. Fibrinogen was measured locally at the central laboratories of the Bronx VA Medical Center using the Beckman Coulter ACL Advance (Beckman Coulter, Inc., Fullerton, California, USA) by the method of clot curve analysis. Patients were followed up for the occurrence of death (all-cause mortality), myocardial infarction (MI; fatal or nonfatal), and stroke. All strokes were confirmed with either magnetic resonance imaging or computed tomography scan. Transient ischemic attacks were not classified as strokes.
Patients were divided into tertiles according to their baseline ADMA levels, and two groups were formed by combining the lower two tertiles and comparing them with the upper tertile. The tertile cutoff values were derived from the original cohort of 389 patients that constituted the database; these cutoff values were then applied to the ACS subpopulation for the present analysis. Summary statistics for the continuous variables (including the biomarkers) were presented as means ± SDs and medians (interquartile ranges), and comparisons between the two groups were performed with the nonparametric Wilcoxon's rank-sum test. Log transformation was applied to all biomarkers to decrease the skewness and kurtosis of the data. Categorical data were summarized as frequencies and percentages, and comparisons between groups were performed with the Pearson's w 2 test or Fisher's exact test if the number of observations per cell was less than five.
The predictors of (i) all-cause mortality, (ii) MI, and (iii) the composite outcome of death (any), MI (fatal or nonfatal), or stroke (all at 24 months) were identified by univariate Cox regression. For each of the three endpoints, the following same baseline variables were studied by univariate analyses: age, family history of premature CAD, diabetes mellitus, hypertension, active tobacco use, history of tobacco use, hyperlipidemia, serum creatinine, BMI, congestive heart failure on presentation, MI on presentation, aspirin use, b-blocker use, angiotensinconverting enzyme inhibitor use, statin use, prior coronary artery bypass graft, number of diseased coronary arteries, left ventricular function, hs-CRP, fibrinogen, and ADMA. Fibrinogen and hs-CRP were analyzed as continuous variables, and the hazard ratios represented an increase of 1 SD in the respective log-transformed biomarker. ADMA was analyzed as a categorical variable, comparing the lower two tertiles with the highest tertile. Only those univariate predictors with a P value of less than 0.05 were subsequently entered into multivariate models. Multivariate Cox proportional hazard analyses were then performed as stepwise regressions with backward elimination to identify the independent predictors.
Time-to-event at 24 months was presented with the Kaplan-Meier curves for each of the endpoints described above. Comparison between the two groups (i.e. combined lower two tertiles vs. upper tertile) was performed with the log-rank test.
All analyses used two-sided tests with an overall significance level of a = 0.05. All statistical analyses were performed using SAS (version 8) statistical software package (SAS Institute Inc., Cary, North Carolina, USA).
Results
In total, 193 men were enrolled in the study. ADMA values were available for 182 of these patients. Baseline characteristics of the study population stratified by the upper tertile of ADMA values (i.e. 1.115 vs. Z 1.115 mmol/l) are listed in Table 1 . Compared with both White and Hispanic patients, a higher proportion of Black patients had ADMA values lower than 1.115 mmol/l. Two-year follow-up data were available for all patients. In the entire cohort of ACS patients, there were a total of 26 deaths (13.5%), of which 15 were classified as cardiac in origin (7.8%). Similarly, there were 37 MIs (19.2%) and 12 strokes (6.2%). The total number of events for the composite outcome of death (all cause), MI (fatal or nonfatal), or stroke was 52 (26.9%). Together with ADMA (analyzed as a categorical variable), all baseline clinical, laboratory, and angiographic variables listed in Methods that were significant for their associations with clinical outcomes with P values less than 0.05 were entered into multivariate models to identify the independent predictors of outcomes (three separate models for each of the three endpoints studied; Table 2 ). After adjustment for these factors, ADMA was found to be a strong and independent predictor of all-cause mortality at 24 months, with a hazard ratio of 2.45 [95% confidence interval (CI): 1.08-5.57; P = 0.0325] when comparing the upper tertile with the combined lower two tertiles. Similarly, for the endpoint of MI, ADMA was also a strong and independent predictor of this outcome, with a hazard ratio of 2.28 (95% CI: 1.14-4.57; P = 0.0204) for the upper tertile compared with the combined lower two tertiles. Finally, for the composite outcome of death, MI or stroke, ADMA was once again an independent predictor for this composite outcome with hazard ratio of 1.81 (95% CI: 1.01-3.25; P = 0.0482) when comparing the upper tertile with the combined lower two tertiles.
Using the upper tertile of ADMA values as a prespecified cutoff (i.e. 1.115 vs. Z 1.115 mmol/l), the Kaplan-Meier curves were derived for each of the three outcomes studied. The Kaplan-Meier plots showed a significant increase in all-cause mortality for patients with ADMA values in the highest tertile (i.e. Z 1.115 mmol/l). At 24 months, the survival rate was 76.2% for the highest tertile, compared with 91.4% for the lower two tertiles combined (P = 0.0040 by log-rank test) (Fig. 1) . For MI, the MI-free survival rate was 72.6% for the highest tertile, compared with 86.8% for the lower two tertiles combined (P = 0.0245 by log-rank test) (Fig. 2) . Finally, for the composite outcome of death, MI or stroke, the event-free survival rate was 61.9% for the highest tertile, compared with 80.3% for the lower two tertiles combined (P = 0.0130 by log-rank test) (Fig. 3) .
Discussion
The most significant finding of this study was that elevated plasma levels of ADMA were powerful and Hyperlipidemia was diagnosed in patients who had been given lipid-lowering medication or had a history of total cholesterol levels > 240 mg/dl [16] . c Takes into account the left main, left anterior descending, left circumflex, and right coronary arteries.
independent predictors of adverse cardiovascular outcomes in patients with ACS referred for coronary angiography. Despite a relatively small number of patients, elevated ADMA levels were an independent predictor of not only the composite outcome of death, MI, or stroke, but also of the individual hard endpoints of all-cause mortality and MI. We believe that the consistency of the association with various cardiovascular outcomes supports the validity of the findings. In addition, and importantly, baseline plasma levels of ADMA were predictors of adverse events even after adjustment for a number of clinically significant covariates known to be powerful predictors of outcomes in patients with ACS, such as age, the presence of myocardial infarction on presentation, left ventricular systolic function, the extent of angiographic CAD, renal function, and established inflammatory biomarkers like fibrinogen and hs-CRP.
Plasma levels of ADMA have been shown to be elevated in patients with cardiovascular risk factors such as hypertension, diabetes, and hypercholesterolemia [4, 6, 18] . In addition, elevated levels of ADMA have been associated with adverse cardiovascular outcomes in a variety of different patient populations, including those with diabetes [9, 10] , peripheral arterial disease [12] , endstage renal disease [11] , as well as those with established CAD referred for angiography for a variety of indications [15] . However, there are limited data in patients with ACS. In a recent small study, Bae et al. [19] demonstrated that patients with ACS had significantly elevated ADMA concentrations compared with age-matched healthy control participants, and that the concentrations rapidly decreased after short-term medical therapy. However, the prognostic significance of these elevated levels was not investigated in that study. In another study, Krempl and colleagues [14] found that patients with unstable angina had significantly higher baseline ADMA levels compared with patients with stable angina. There was a significant reduction of ADMA levels at 6 weeks after percutaneous coronary intervention in patients with unstable angina who experienced no recurrent cardiovascular event. In contrast, patients with unstable angina who had an event showed no significant decrease in ADMA at 6 weeks. Actuarial survival analysis showed a significantly higher The Kaplan-Meier curves for the outcome of all-cause mortality comparing the upper tertile of baseline asymmetric dimethylarginine (ADMA) values with the lower two tertiles combined. At 24 months, the number of patients who had died in the upper tertile was 15 (23.8%) compared with 10 (8.6%) in the lower two tertiles combined (P = 0.0040 by log-rank test). event rate in patients with persistently elevated ADMA plasma concentrations. However, that study was small (consisting of only 81 patients), restricted to those with unstable angina (not the full spectrum of ACS), and the duration of follow-up was relatively short (only 1 year). In a larger study consisting of a broad population of patients with proven CAD (including some with ACS), elevated ADMA levels were strong predictors of adverse events, even after adjustment for the presence of ACS [15] . However, to our knowledge, this study is the first to report on the long-term prognostic significance of elevated ADMA levels in a population consisting exclusively of ACS patients. Importantly, our study included patients across the full spectrum of the current definition of ACS, including and limited to those with troponin-negative unstable angina, NSTEMI, and STEMI.
The mechanism(s) by which ADMA levels are associated with adverse outcomes in ACS is unknown but may involve oxidative stress. There is experimental evidence to suggest a putative role of oxidative stress in CAD in general and the ACS in particular [20] [21] [22] [23] . Indeed, the ACS are characterized by elevated oxidative stress and cytokine production, and it has been proposed that the interaction between chemokines and oxidative stress in unstable CAD may represent a vicious cycle involved in the pathogenesis of the ACS [21] . Furthermore, oxidative stress itself can lead to elevation of ADMA through a variety of mechanisms [14, 24, 25] . Therefore, elevation of ADMA in patients with ACS may reflect increased oxidative stress, which along with elevated ADMA levels may lead to endothelial dysfunction and help explain the relationship with adverse outcomes during follow-up. ACS patients with the highest ADMA levels may therefore represent those with the greatest oxidative stress, and thus potentially those at the highest risk.
There are several limitations to this study. First, it was conducted exclusively in men, and as such the results cannot be extrapolated to women. Second, the size of our population was small, and the study was not designed with a priori calculations with respect to sample size or statistical power. As such, the findings need to be confirmed in larger and prospectively designed studies.
In conclusion, we found that elevated baseline plasma levels of ADMA are independently associated with an increased risk of both death and MI (as individual endpoints) at 2-year follow-up in a cohort of men with ACS referred for coronary angiography. Furthermore, the prognostic ability of ADMA in this regard seems to be independent of inflammatory markers such as hs-CRP or fibrinogen. These findings are both consistent with, and extend, the earlier reports on the prognostic significance of baseline ADMA levels in a variety of different populations to those presenting with an acute coronary syndrome.
